Motif Bio Seeks Cash For Novel Antibiotic
Motif Bio wants to raise £19.4m to further develop iclaprim, its novel antibiotic candidate for acute bacterial skin and skin structure infections.
You may also be interested in...
Regulatory uncertainty could imperil the crop of emerging companies making a go of it in the incentive-laden US anti-infective space.
Biotech firm hopes its once-shelved antibiotic will provide a therapeutic option for renally impaired patients with serious skin infections. With only one previous DHFR inhibitor ever approved, Motif also anticipates that iclaprim will offer an option for multidrug-resistant infections.
Immuno-oncology continued to dominate pharma alliances in 2016, and cancer was once again the leading therapeutic area by volume in both partnerships and financings. Pfizer rebounded from its failed Allergan takeover in 2015 to do the largest M&A of 2016, Medivation.